Coverage

PharmaVOICE.com  A US industry digital news website said," NOXCOVID-1 is looking at treating those COVID-19 patients hospitalized with moderate lung dysfunction requiring low oxygen support who are at risk of progressing rapidly into requiring intensive care and mechanical ventilation".

Click here to read more

Bloomberg reported on Noxopharm's October 2, 2020 ASX announcement Noxopharm Announces First COVID-19 Patient Treated in Veyonda® Study

Click here to read more

BioWorld, in its In The Clinic section, reported on Noxopharm's NOXCOVID trial first COVID patient's treatment; "Treated first patient in Noxcovid-1 study enrolling subjects hospitalized with moderate lung dysfunction requiring low oxygen support who are at risk of progressing rapidly into requiring intensive care and mechanical ventilation".

Click here to read more

BioSpace, a US Life Sciences industry digital hub reported," Noxopharm Announces First COVID-19 Patient Treated in Veyonda® Study

Click here to read more

Global biotech news service, BioWorld, in its Other News To Note, covered Noxopharm's reporting (11 Aug 2020) that, " Independent research published in European Urology Oncology showed the combination of 177Lu-PSMA-617 radioligand therapy and Veyonda (idronoxil), its sphingosine-1-phosphate inhibitor, was safe and effective, with median overall survival (OS) of 17.1 months in late-stage prostate cancer patients who exhausted standard treatment options. Median OS in a study conducted in a comparable population who received standard chemotherapy was 4.5 months." 

Click here to read more.

US Life Science website, Clinical Research News, said Noxopharm had announced new research showing Veyonda^® cancer survival rates in a peer-reviewed publication, European Urology Oncology,  the first official publication of the European Association of Urology that is fully devoted to the study of genitourinary cancer.

Click here to read more.

Pharmaceutical news digital site, FirstWord Pharma, continued coverage on Noxopharm's lead drug candidate, Veyonda^®'s trials in late -stage prostate cancer.

Click here to read more.

PharmaVOICE.com provided the news release, "Noxopharm Announces New Research Showing Veyonda^® Cancer Survival Rates" which reported that the Australian clinical-stage drug development company announced the publication of the first manuscript of the LuPIN trial in the journal, European Urology Oncology. This journal is the first official publication of the European Association of Urology that is fully devoted to the study of genitourinary cancer.

Click here to read more.

Life Sciences digital hub, BioSpace, reported on Noxopharm's announcement (11 August 2020) regarding the details of the peer-reviewed publication of key LuPIN (Phase 2) study data in its ongoing late-stage prostate cancer trial.

Click here to read more.

US website Clinical Research News reported on Noxopharm's pre-clinical announcement concerning idronoxil's ability to convert 'cold' cancer tumours to 'hot' ones in the laboratory.

Click here to read more.